Cargando…

Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database

INTRODUCTION: Parkinson's disease (PD) treatment should follow guidelines and be tailored to each patient. Large database analyses can provide insights into prescribing patterns. METHODS: Retrospective, cross-sectional study of patients (≥30 years) with PD diagnosis (ICD-10; schizophrenia/cereb...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Masahiko, Arai, Masaki, Hayashi, Ayako, Ogino, Mieko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397691/
https://www.ncbi.nlm.nih.gov/pubmed/32775705
http://dx.doi.org/10.1016/j.ensci.2020.100257
_version_ 1783565821415522304
author Suzuki, Masahiko
Arai, Masaki
Hayashi, Ayako
Ogino, Mieko
author_facet Suzuki, Masahiko
Arai, Masaki
Hayashi, Ayako
Ogino, Mieko
author_sort Suzuki, Masahiko
collection PubMed
description INTRODUCTION: Parkinson's disease (PD) treatment should follow guidelines and be tailored to each patient. Large database analyses can provide insights into prescribing patterns. METHODS: Retrospective, cross-sectional study of patients (≥30 years) with PD diagnosis (ICD-10; schizophrenia/cerebrovascular disease excluded) using health insurance claims data (April 2008–December 2016) from the Japan Medical Data Vision database. Prescription patterns of anti-PD drugs were analysed by patient age and sex, calendar year, and overall. RESULTS: The analysis comprised 155,493 PD patient-years (56.1% women, mean 73.4 years). Patient number increased each year, mainly because of database expansion. L-dopa as monotherapy was the most common prescription (22.7% of patient-years); non-ergot dopamine agonists (DAs) were also common (7.6% as monotherapy, 6.8% with L-dopa). Monotherapy was prescribed for ~50% of patient-years, two drugs for 14.1%, and at least three drugs for 18.4%. Consistent with Japanese guidelines, L-dopa was mostly prescribed to older patients (≥60 years), whereas non-ergot DAs were mostly prescribed to middle-aged patients (peak at 50–69 years). Between 2008 and 2011, L-dopa prescription decreased while that of non-ergot DAs increased; this pattern reversed between 2012 and 2016. CONCLUSION: These results indicate that Japanese clinicians are adhering to Japanese guidelines and tailoring anti-PD treatment to individual patients.
format Online
Article
Text
id pubmed-7397691
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73976912020-08-06 Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database Suzuki, Masahiko Arai, Masaki Hayashi, Ayako Ogino, Mieko eNeurologicalSci Original Article INTRODUCTION: Parkinson's disease (PD) treatment should follow guidelines and be tailored to each patient. Large database analyses can provide insights into prescribing patterns. METHODS: Retrospective, cross-sectional study of patients (≥30 years) with PD diagnosis (ICD-10; schizophrenia/cerebrovascular disease excluded) using health insurance claims data (April 2008–December 2016) from the Japan Medical Data Vision database. Prescription patterns of anti-PD drugs were analysed by patient age and sex, calendar year, and overall. RESULTS: The analysis comprised 155,493 PD patient-years (56.1% women, mean 73.4 years). Patient number increased each year, mainly because of database expansion. L-dopa as monotherapy was the most common prescription (22.7% of patient-years); non-ergot dopamine agonists (DAs) were also common (7.6% as monotherapy, 6.8% with L-dopa). Monotherapy was prescribed for ~50% of patient-years, two drugs for 14.1%, and at least three drugs for 18.4%. Consistent with Japanese guidelines, L-dopa was mostly prescribed to older patients (≥60 years), whereas non-ergot DAs were mostly prescribed to middle-aged patients (peak at 50–69 years). Between 2008 and 2011, L-dopa prescription decreased while that of non-ergot DAs increased; this pattern reversed between 2012 and 2016. CONCLUSION: These results indicate that Japanese clinicians are adhering to Japanese guidelines and tailoring anti-PD treatment to individual patients. Elsevier 2020-07-16 /pmc/articles/PMC7397691/ /pubmed/32775705 http://dx.doi.org/10.1016/j.ensci.2020.100257 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Suzuki, Masahiko
Arai, Masaki
Hayashi, Ayako
Ogino, Mieko
Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
title Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
title_full Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
title_fullStr Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
title_full_unstemmed Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
title_short Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
title_sort prescription pattern of anti-parkinson's disease drugs in japan based on a nationwide medical claims database
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397691/
https://www.ncbi.nlm.nih.gov/pubmed/32775705
http://dx.doi.org/10.1016/j.ensci.2020.100257
work_keys_str_mv AT suzukimasahiko prescriptionpatternofantiparkinsonsdiseasedrugsinjapanbasedonanationwidemedicalclaimsdatabase
AT araimasaki prescriptionpatternofantiparkinsonsdiseasedrugsinjapanbasedonanationwidemedicalclaimsdatabase
AT hayashiayako prescriptionpatternofantiparkinsonsdiseasedrugsinjapanbasedonanationwidemedicalclaimsdatabase
AT oginomieko prescriptionpatternofantiparkinsonsdiseasedrugsinjapanbasedonanationwidemedicalclaimsdatabase